Efficacy and safety of levodopa with entacapone in Parkinson's disease patients suboptimally controlled with levodopa alone, in daily clinical practice: An international, multicentre, open-label study

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 6, 2003, Pages 963-971

  Gershanik, Oscar ^a   Emre, Murat ^b   Bernhard, Gudrun ^c   Sauer, Dirk ^c  

^a HOSPITAL FRANCÉS   (Argentina)

^b ISTANBUL UNIVERSITY   (Turkey)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Efficacy; Entacapone; Levodopa; Parkinson's disease

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA;

ADULT; AGED; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; FALLING; FEMALE; GASTROINTESTINAL SYMPTOM; HEAD INJURY; HUMAN; KIDNEY DISEASE; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PSYCHOSIS; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; URINALYSIS; URINE RETENTION;

EID: 0141851875     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00156-8     Document Type: Article

References (24)

1. Agid Y., Olanow C.W., Mizuno Y. Levodopa: why the controversy? Lancet. 360:2002;575.
2. Brooks D.J., Sagar H. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study. J. Neurol. Neurosurg. Psychiatry. 74(8):2003;1064-1072.
3. Durif F., Devaux I., Pere J.J., Delumeau J.C., Bourdeix I. Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur. Neurol. 45:2001;111-118.
4. Fénelon G., Giménez-Roldán S., Montastruc J.L., Bermejo F., Durif F., Bourdeix I., Pére J.-J., Galiano L., Schadrack J. Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized double-blind, multicentre study. J. Neural Transm. 110:2003;239-251.
5. Gelijns A.C., Rosenberg N., Moskowitz A.J. Capturing the unexpected benefits of medical research. N. Engl. J. Med. 339:1998;693-698.
6. Hauser R.A., Koller W.C., Hubble J.P., Malapira T., Busenbark K., Olanow C.W. Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. Mov. Disord. 15:2000;485-489.
7. Hubble J., Schumock G., Markowitz J., Gutterman E. Entacapone and quality of life in patients with Parkinson's disease: results of the response initiative program. Neurol. Rev. 2000;11-16. (Suppl.).
8. Kaakkola S., Gordin A., Mannisto P.T. General properties and clinical possibilities of new selective inhibitors of catechol-O-methyltransferase. Gen. Pharmacol. 25:1994;813-824.
9. Marinus J., Ramaker C., van Hilten J.J., Stiggelbout A.M. Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments. J. Neurol. Neurosurg. Psychiatry. 72:2002;241-248.
10. Myllyla V.V., Kultalahti E.R., Haapaniemi H., Leinonen M. Twelve-month safety of entacapone in patients with Parkinson's disease. Eur. J. Neurol. 8:2001;53-60.
11. Nutt J.G., Holford N.H. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann. Neurol. 39:1996;561-573.
12. Nutt J.G., Woodward W.R., Beckner R.M., Stone C.K., Berggren K., Carter J.H., Gancher S.T., Hammerstad J.P., Gordin A. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology. 44:1994;913-919.
13. Parkinson Study Group Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann. Neurol. 42:1997;747-755.
14. Peto V., Jenkinson C., Fitzpatrick R., Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual. Life Res. 4:1995;241-248.
15. Poewe W.H., Deuschl G., Gordin A., Kultalahti E.R., Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol. Scand. 105:2002;245-255.
16. Rinne U.K., Larsen J.P., Siden A., Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations, Nomecomt Study Group. Neurology. 51:1998;1309-1314.
17. Rubenstein L.M., Voelker M.D., Chrischilles E.A., Glenn D.C., Wallace R.B., Rodnitzky R.L. The usefulness of the Functional Status Questionnaire and Medical Outcomes Study Short Form in Parkinson's disease research. Qual. Life Res. 7:1998;279-290.
18. Ruottinen H.M., Rinne U.K. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin. Neuropharmacol. 19:1996;283-296.
19. Scheife R.T., Schumock G.T., Burstein A., Gottwald M.D., Luer M.S. Impact of Parkinson's disease and its pharmacologic treatment on quality of life and economic outcomes. Am. J. Health-Syst. Pharm. 57:2000;953-962.
20. Schrag A., Jahanshahi M., Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov. Disord. 15:2000;1112-1118.
21. Stocchi F., De Pandis M.F., Vacca L., Valente M., Brusa L., Ruggieri S. Entacapone efficacy in Parkinson's disease. Mov. Disord. 15(Suppl. 3):2000;127.
22. Watkins P. COMT inhibitors and liver toxicity. Neurology. 55:2000;S51-S52. (discussion S53-S56).
23. Wheatley K., Stowe R.L., Clarke C.E., Hills R.K., Williams A.C., Gray R. Evaluating drug treatments for Parkinson's disease: how good are the trials? BMJ. 324:2002;1508-1511.
24. Zappia M., Oliveri R.L., Montesanti R., Rizzo M., Bosco D., Plastino M., Crescibene L., Bastone L., Aguglia U., Gambardella A., Quattrone A. Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology. 52:1999;763-767.